{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T07:06:02Z","timestamp":1766732762514,"version":"3.37.3"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s11010-022-04552-8","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T13:06:58Z","timestamp":1663074418000},"page":"807-820","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of selected antidiabetics in cardiovascular complications associated with cancer cachexia"],"prefix":"10.1007","volume":"478","author":[{"given":"Vivek R.","family":"Bora","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhruv","family":"Gohel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0594-5452","authenticated-orcid":false,"given":"Bhoomika M.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,13]]},"reference":[{"key":"4552_CR1","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1093\/eurheartj\/eht302","volume":"35","author":"Springer","year":"2014","unstructured":"Springer, Tschirner, Haghikia, Von Haehling, Lal, Grzesiak et al (2014) Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. Eur Heart J 35:932\u2013941. https:\/\/doi.org\/10.1093\/eurheartj\/eht302","journal-title":"Eur Heart J"},{"key":"4552_CR2","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.lfs.2010.12.010","volume":"88","author":"Xu","year":"2011","unstructured":"Xu et al (2011) Myocardial dysfunction in an animal model of cancer cachexia. Life Sci 88:406\u2013410. https:\/\/doi.org\/10.1016\/j.lfs.2010.12.010","journal-title":"Life Sci"},{"key":"4552_CR3","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"Fearon","year":"2011","unstructured":"Fearon et al (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12:489\u2013495. https:\/\/doi.org\/10.1016\/S1470-2045(10)70218-7","journal-title":"Lancet Oncol"},{"key":"4552_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.smhs.2020.10.003","volume":"2","author":"Lim","year":"2020","unstructured":"Lim et al (2020) Development and progression of cancer cachexia: perspectives from bench to bedside. Sports Med Health Sci 2:177\u2013185. https:\/\/doi.org\/10.1016\/j.smhs.2020.10.003","journal-title":"Sports Med Health Sci"},{"key":"4552_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.yjmcc.2015.05.007","volume":"85","author":"Stevens","year":"2015","unstructured":"Stevens et al (2015) Losartan treatment attenuates tumor-induced myocardial dysfunction. J Mol Cell Cardiol 85:37\u201347. https:\/\/doi.org\/10.1016\/j.yjmcc.2015.05.007","journal-title":"J Mol Cell Cardiol"},{"key":"4552_CR6","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3389\/fonc.2020.00298","volume":"10","author":"Marceca","year":"2020","unstructured":"Marceca et al (2020) Management of cancer cachexia: attempting to develop new pharmacological agents for new effective therapeutic options. Front Oncol 10:298. https:\/\/doi.org\/10.3389\/fonc.2020.00298","journal-title":"Front Oncol"},{"key":"4552_CR7","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.hjc.2016.12.003","volume":"58","author":"X Li","year":"2017","unstructured":"Li X et al (2017) Cardiac complications in cancer treatment\u2014a review. Hell J Cardiol 58:190\u2013193. https:\/\/doi.org\/10.1016\/j.hjc.2016.12.003","journal-title":"Hell J Cardiol"},{"key":"4552_CR8","doi-asserted-by":"publisher","DOI":"10.1200\/OP.20.00924","author":"K Stone","year":"2021","unstructured":"Stone K et al (2021) Monitoring for chemotherapy-related cardiotoxicity in the form of left ventricular systolic dysfunction\u202f: a review of current recommendations. JCO Oncol Pract. https:\/\/doi.org\/10.1200\/OP.20.00924","journal-title":"JCO Oncol Pract"},{"key":"4552_CR9","doi-asserted-by":"publisher","first-page":"H466","DOI":"10.1152\/ajpheart.00720.2015","volume":"310","author":"Murphy","year":"2016","unstructured":"Murphy (2016) The pathogenesis and treatment of cardiac atrophy in cancer cachexia. Am J Physiol\u2014Heart Circ Physiol 310:H466\u2013H477. https:\/\/doi.org\/10.1152\/ajpheart.00720.2015","journal-title":"Am J Physiol\u2014Heart Circ Physiol"},{"key":"4552_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/ehjcvp\/pvv035","volume":"2","author":"Kumar","year":"2016","unstructured":"Kumar et al (2016) Cardiovascular safety of anti-diabetic drugs. Eur Heart J\u2014Cardiovasc Pharmacother 2:32\u201343. https:\/\/doi.org\/10.1093\/ehjcvp\/pvv035","journal-title":"Eur Heart J\u2014Cardiovasc Pharmacother"},{"key":"4552_CR11","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1111\/j.1464-410X.2011.10555.x","volume":"109","author":"Nobes","year":"2012","unstructured":"Nobes et al (2012) A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. BJU Int 109:1495\u20131502. https:\/\/doi.org\/10.1111\/j.1464-410X.2011.10555.x","journal-title":"BJU Int"},{"key":"4552_CR12","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s00380-015-0724-7","volume":"31","author":"Hashikata","year":"2016","unstructured":"Hashikata, Yamaoka-Tojo, Kakizaki, Nemoto, Fujiyoshi, Namba et al (2016) Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes. Heart and Vessels 31:1303\u20131310. https:\/\/doi.org\/10.1007\/s00380-015-0724-7","journal-title":"Heart and Vessels"},{"key":"4552_CR13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jchf.2017.08.004","volume":"6","author":"McMurray","year":"2018","unstructured":"McMurray, Ponikowski, Bolli, Lukashevich, Kozlovski, Kothny et al (2018) Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial. JACC Heart Fail 6:8\u201317. https:\/\/doi.org\/10.1016\/j.jchf.2017.08.004","journal-title":"JACC Heart Fail"},{"key":"4552_CR14","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1021\/acsptsci.0c00144","volume":"3","author":"A-K Eliaa","year":"2020","unstructured":"Eliaa A-K et al (2020) Empagliflozin and doxorubicin synergistically inhibit the survival of triple-negative breast cancer cells via interfering with the mTOR pathway and inhibition of calmodulin. In vitro and molecular docking studies. ACS Pharmacol Transl Sci 3:1330\u20131338. https:\/\/doi.org\/10.1021\/acsptsci.0c00144","journal-title":"ACS Pharmacol Transl Sci"},{"key":"4552_CR15","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00204-020-02951-8","volume":"95","author":"Chang","year":"2020","unstructured":"Chang et al (2020) Dapagliflozin suppresses ER stress and protects doxorubicin-induced cardiotoxicity in breast cancer patients. Arch Toxicol 95:659\u2013671. https:\/\/doi.org\/10.1007\/s00204-020-02951-8","journal-title":"Arch Toxicol"},{"key":"4552_CR16","doi-asserted-by":"publisher","first-page":"119329","DOI":"10.1016\/J.LFS.2021.119329","volume":"274","author":"Bora","year":"2021","unstructured":"Bora, Patel (2021) Investigation into the role of anti-diabetic agents in cachexia associated with metastatic cancer. Life Sci 274:119329. https:\/\/doi.org\/10.1016\/J.LFS.2021.119329","journal-title":"Life Sci"},{"key":"4552_CR17","doi-asserted-by":"publisher","first-page":"737","DOI":"10.4161\/cbt.12.8.16442","volume":"12","author":"J Li","year":"2011","unstructured":"Li J et al (2011) Hydrodynamic cell delivery for simultaneous establishment of tumor growth in mouse lung, liver and kidney. Cancer Biol Ther 12:737\u2013741. https:\/\/doi.org\/10.4161\/cbt.12.8.16442","journal-title":"Cancer Biol Ther"},{"key":"4552_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep27295","volume":"6","author":"S Wang","year":"2016","unstructured":"Wang S, Yang Ma, Li C et al (2016) Activation of liver X receptor inhibits the development of pulmonary carcinomas induced by 3-methylcholanthrene and butylated hydroxytoluene in BALB\/c mice. Sci Rep 6:1\u201311. https:\/\/doi.org\/10.1038\/srep27295","journal-title":"Sci Rep"},{"key":"4552_CR19","doi-asserted-by":"publisher","first-page":"87","DOI":"10.4103\/0976-500X.72350","volume":"1","author":"Parasuraman","year":"2010","unstructured":"Parasuraman et al (2010) Blood sample collection in small laboratory animals. J Pharmacol Pharmacother 1:87\u201393. https:\/\/doi.org\/10.4103\/0976-500X.72350","journal-title":"J Pharmacol Pharmacother"},{"key":"4552_CR20","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s11010-008-9772-y","volume":"314","author":"Goyal","year":"2008","unstructured":"Goyal et al (2008) Effect of telmisartan on cardiovascular complications associated with streptozotocin diabetic rats. Mol Cell Biochem 314:123\u2013131. https:\/\/doi.org\/10.1007\/s11010-008-9772-y","journal-title":"Mol Cell Biochem"},{"key":"4552_CR21","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S1734-1140(11)70611-9","volume":"63","author":"Goyal","year":"2011","unstructured":"Goyal et al (2011) Beneficial role of telmisartan on cardiovascular complications associated with STZ-induced type 2 diabetes in rats. Pharmacol Rep 63:956\u2013966. https:\/\/doi.org\/10.1016\/S1734-1140(11)70611-9","journal-title":"Pharmacol Rep"},{"key":"4552_CR22","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1097\/FJC.0b013e3181be75cc","volume":"54","author":"Goyal","year":"2009","unstructured":"Goyal et al (2009) Investigation into the cardiac effects of spironolactone in the experimental model of type 1 diabetes. J Cardiovasc Pharmacol 54:502\u2013509. https:\/\/doi.org\/10.1097\/FJC.0b013e3181be75cc","journal-title":"J Cardiovasc Pharmacol"},{"key":"4552_CR23","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1055\/s-0033-1345168","volume":"121","author":"BM Patel","year":"2013","unstructured":"Patel BM et al (2013) Effect of spironolactone on cardiovascular complications associated with type-2 diabetes in rats. Exp Clin Endocrinol Diabetes 121:441\u2013447. https:\/\/doi.org\/10.1055\/s-0033-1345168","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"4552_CR24","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejphar.2014.01.063","volume":"728","author":"BM Patel","year":"2014","unstructured":"Patel BM et al (2014) Cardioprotective effects of magnesium valproate in type 2 diabetes mellitus. Eur J Pharmacol 728:128\u2013134. https:\/\/doi.org\/10.1016\/j.ejphar.2014.01.063","journal-title":"Eur J Pharmacol"},{"key":"4552_CR25","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3109\/10641963.2013.827699","volume":"36","author":"BM Patel","year":"2014","unstructured":"Patel BM, Bhadada (2014) Type 2 diabetes-induced cardiovascular complications: comparative evaluation of spironolactone, atenolol, metoprolol, ramipril and perindopril. Clin Exp Hypertens 36:340\u2013347. https:\/\/doi.org\/10.3109\/10641963.2013.827699","journal-title":"Clin Exp Hypertens"},{"key":"4552_CR26","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1139\/cjpp-2013-0348","volume":"92","author":"Rayabarapu","year":"2014","unstructured":"Rayabarapu, Patel (2014) Beneficial role of tamoxifen in isoproterenol-induced myocardial infarction. Can J Physiol Pharmacol 92:849\u2013857. https:\/\/doi.org\/10.1139\/cjpp-2013-0348","journal-title":"Can J Physiol Pharmacol"},{"key":"4552_CR27","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.biopha.2017.10.137","volume":"97","author":"Rabadiya","year":"2018","unstructured":"Rabadiya et al (2018) Magnesium valproate ameliorates type 1 diabetes and cardiomyopathy in diabetic rats through estrogen receptors. Biomed Pharmacother 97:919\u2013927. https:\/\/doi.org\/10.1016\/j.biopha.2017.10.137","journal-title":"Biomed Pharmacother"},{"key":"4552_CR28","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1177\/0960327112446817","volume":"31","author":"BM Patel","year":"2012","unstructured":"Patel BM et al (2012) Perindopril protects against streptozotocin-induced hyperglycemic myocardial damage\/alterations. Hum Exp Toxicol 31:1132\u20131143. https:\/\/doi.org\/10.1177\/0960327112446817","journal-title":"Hum Exp Toxicol"},{"key":"4552_CR29","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.pharep.2014.02.004","volume":"66","author":"Patel","year":"2014","unstructured":"Patel et al (2014) Beneficial role of tamoxifen in experimentally induced cardiac hypertrophy. Pharmacol Rep 66:264\u2013272. https:\/\/doi.org\/10.1016\/j.pharep.2014.02.004","journal-title":"Pharmacol Rep"},{"key":"4552_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s12012-018-9470-2","volume":"19","author":"Sharma","year":"2019","unstructured":"Sharma et al (2019) Beneficial effect of silymarin in pressure overload induced experimental cardiac hypertrophy. Cardiovasc Toxicol 19:23\u201335. https:\/\/doi.org\/10.1007\/s12012-018-9470-2","journal-title":"Cardiovasc Toxicol"},{"key":"4552_CR31","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/948427","author":"Raghunathan","year":"2014","unstructured":"Raghunathan et al (2014) Evaluation of buspirone on streptozotocin induced type 1 diabetes and its associated complications. Biomed Res Int. https:\/\/doi.org\/10.1155\/2014\/948427","journal-title":"Biomed Res Int"},{"key":"4552_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-137","author":"C Tsai","year":"2012","unstructured":"Tsai C, Sun Y, Leu C et al (2012) Obesity suppresses circulating level and function of endothelial progenitor cells and heart function. J Transl Med. https:\/\/doi.org\/10.1186\/1479-5876-10-137","journal-title":"J Transl Med"},{"key":"4552_CR33","doi-asserted-by":"publisher","first-page":"33789","DOI":"10.1074\/jbc.M602118200","volume":"281","author":"Nojiri","year":"2006","unstructured":"Nojiri, Shimizu, Funakoshi, Yamaguchi, Zhou, Kawakami et al (2006) Oxidative stress causes heart failure with impaired mitochondrial respiration. J Biol Chem 281:33789\u201333801. https:\/\/doi.org\/10.1074\/jbc.M602118200","journal-title":"J Biol Chem"},{"key":"4552_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejphar.2014.09.025","volume":"743","author":"Y Tsubouchi","year":"2014","unstructured":"Tsubouchi Y et al (2014) Ghrelin relieves cancer cachexia associated with the development of lung adenocarcinoma in mice. Eur J Pharmacol 743:1\u201310. https:\/\/doi.org\/10.1016\/j.ejphar.2014.09.025","journal-title":"Eur J Pharmacol"},{"key":"4552_CR35","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.lfs.2016.11.033","volume":"170","author":"HJ Patel","year":"2017","unstructured":"Patel HJ, Patel (2017) TNF-\u03b1 and cancer cachexia: Molecular insights and clinical implications. Life Sci 170:56\u201363. https:\/\/doi.org\/10.1016\/j.lfs.2016.11.033","journal-title":"Life Sci"},{"key":"4552_CR36","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.3892\/ijo.2011.1150","volume":"39","author":"A Tian","year":"2011","unstructured":"Tian A et al (2011) Evidence for cardiac atrophic remodeling in cancer-induced cachexia in mice. Int J Oncol 39:1321\u20131326. https:\/\/doi.org\/10.3892\/ijo.2011.1150","journal-title":"Int J Oncol"},{"key":"4552_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-020-00288-6","author":"Rausch","year":"2021","unstructured":"Rausch et al (2021) Understanding the common mechanisms of heart and skeletal muscle wasting in cancer cachexia. Oncogenesis. https:\/\/doi.org\/10.1038\/s41389-020-00288-6","journal-title":"Oncogenesis"},{"key":"4552_CR38","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1161\/CIRCULATIONAHA.113.001879","volume":"128","author":"Xie","year":"2013","unstructured":"Xie et al (2013) Pathological ventricular remodeling: therapies: part 2 of 2. Circulation 128:1021\u20131030. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.001879","journal-title":"Circulation"},{"key":"4552_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1110-6","author":"Nissen","year":"2019","unstructured":"Nissen et al (2019) Collagens and cancer associated fibroblasts in the reactive stroma and its relation to cancer biology. J Exp Clin Cancer Res. https:\/\/doi.org\/10.1186\/s13046-019-1110-6","journal-title":"J Exp Clin Cancer Res"},{"key":"4552_CR40","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.3892\/or.2017.5542","volume":"37","author":"Belloum","year":"2017","unstructured":"Belloum et al (2017) Cancer-induced cardiac cachexia: pathogenesis and impact of physical activity (Review). Oncol Rep 37:2543\u20132552. https:\/\/doi.org\/10.3892\/or.2017.5542","journal-title":"Oncol Rep"},{"key":"4552_CR41","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1161\/hs0102.101544","volume":"33","author":"Ay","year":"2002","unstructured":"Ay et al (2002) Creatine kinase-MB elevation after stroke is not cardiac in origin comparison with troponin T levels. Stroke 33:286\u2013289. https:\/\/doi.org\/10.1161\/hs0102.101544","journal-title":"Stroke"},{"key":"4552_CR42","doi-asserted-by":"publisher","first-page":"735","DOI":"10.12816\/amj.2020.82588","volume":"49","author":"Abul-fadle","year":"2020","unstructured":"Abul-fadle et al (2020) Effect of spexin treatment on cardiometabolic changes in obese type 2 by. Al-Azhar Med J 49:735\u2013758. https:\/\/doi.org\/10.12816\/amj.2020.82588","journal-title":"Al-Azhar Med J"},{"key":"4552_CR43","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S166157","volume-title":"Biomarkers in acute myocardial infarction: current perspectives. Vascular health and risk management","author":"Aydin","year":"2019","unstructured":"Aydin et al (2019) Biomarkers in acute myocardial infarction: current perspectives. Vascular health and risk management. Dove Medical Press Ltd, Macclesfield. https:\/\/doi.org\/10.2147\/VHRM.S166157"},{"key":"4552_CR44","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1161\/01.HYP.0000053446.43894.9F","volume":"41","author":"Fedorova","year":"2003","unstructured":"Fedorova et al (2003) Myocardial PKC \u03b22 and the sensitivity of Na\/K-ATPase to marinobufagenin are reduced by cicletanine in Dahl hypertension. Hypertension 41:505\u2013511. https:\/\/doi.org\/10.1161\/01.HYP.0000053446.43894.9F","journal-title":"Hypertension"},{"key":"4552_CR45","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00219.2007","author":"Horton","year":"2007","unstructured":"Horton et al (2007) Burn injury decreases myocardial Na-K-ATPase activity: role of PKC inhibition. Am J Physiol\u2014Regul Integr Comp Physiol. https:\/\/doi.org\/10.1152\/ajpregu.00219.2007","journal-title":"Am J Physiol\u2014Regul Integr Comp Physiol"},{"key":"4552_CR46","doi-asserted-by":"publisher","first-page":"6149","DOI":"10.7150\/thno.46053","volume":"10","author":"Sun","year":"2020","unstructured":"Sun et al (2020) DR-region of Na+\/K+-ATPase is a target to ameliorate hepatic insulin resistance in obese diabetic mice. Theranostics 10:6149\u20136166. https:\/\/doi.org\/10.7150\/thno.46053","journal-title":"Theranostics"},{"key":"4552_CR47","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/j.1467-789X.2006.00276.x","volume":"8","author":"Iannello","year":"2007","unstructured":"Iannello et al (2007) Animal and human tissue Na, K-ATPase in normal and insulin-resistant states: regulation, behaviour and interpretative hypothesis on NEFA effects. Obes Rev 8:231\u2013251. https:\/\/doi.org\/10.1111\/j.1467-789X.2006.00276.x","journal-title":"Obes Rev"},{"key":"4552_CR48","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1152\/ajprenal.00420.2010","volume":"301","author":"Seo-Mayer","year":"2011","unstructured":"Seo-Mayer et al (2011) Preactivation of AMPK by metformin may ameliorate the epithelial cell damage caused by renal ischemia. Am J Physiol\u2014Renal Physiol 301:1346. https:\/\/doi.org\/10.1152\/ajprenal.00420.2010","journal-title":"Am J Physiol\u2014Renal Physiol"},{"key":"4552_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2019.00186","author":"Maejima","year":"2020","unstructured":"Maejima (2020) SGLT2 inhibitors play a salutary role in heart failure via modulation of the mitochondrial function. Front Cardiovasc Med. https:\/\/doi.org\/10.3389\/fcvm.2019.00186","journal-title":"Front Cardiovasc Med"},{"key":"4552_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0183664","volume":"12","author":"Hesen","year":"2017","unstructured":"Hesen et al (2017) A systematic review and meta-analysis of the protective effects of metformin in experimental myocardial infarction. PLoS ONE 12:1\u201318. https:\/\/doi.org\/10.1371\/journal.pone.0183664","journal-title":"PLoS ONE"},{"key":"4552_CR51","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10557-013-6504-7","volume":"28","author":"Lexis","year":"2014","unstructured":"Lexis et al (2014) Chronic metformin treatment is associated with reduced myocardial infarct size in diabetic patients with ST-segment elevation myocardial infarction. Cardiovasc Drugs Ther 28:163\u2013171. https:\/\/doi.org\/10.1007\/s10557-013-6504-7","journal-title":"Cardiovasc Drugs Ther"},{"key":"4552_CR52","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1161\/CIRCULATIONAHA.116.024632","volume":"135","author":"Cavender","year":"2017","unstructured":"Cavender et al (2017) Serial measurement of high-sensitivity troponin i and cardiovascular outcomes in patients with type 2 diabetes mellitus in the examine trial (examination of cardiovascular outcomes with alogliptin versus standard of care). Circulation 135:1911\u20131921. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.024632","journal-title":"Circulation"},{"key":"4552_CR53","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jacc.2017.06.016","volume":"70","author":"Januzzi","year":"2017","unstructured":"Januzzi et al (2017) Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes. J Am Coll Cardiol 70:704\u2013712. https:\/\/doi.org\/10.1016\/j.jacc.2017.06.016","journal-title":"J Am Coll Cardiol"},{"key":"4552_CR54","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.ajpath.2010.12.009","volume":"178","author":"Wysong","year":"2011","unstructured":"Wysong et al (2011) NF-\u03baB inhibition protects against tumor-induced cardiac atrophy in vivo. Am J Pathol 178:1059\u20131068. https:\/\/doi.org\/10.1016\/j.ajpath.2010.12.009","journal-title":"Am J Pathol"},{"key":"4552_CR55","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1161\/01.HYP.33.5.1135","volume":"33","author":"Muntzel","year":"1999","unstructured":"Muntzel et al (1999) Metformin attenuates salt-induced hypertension in spontaneously hypertensive rats. Hypertension 33:1135\u20131140. https:\/\/doi.org\/10.1161\/01.HYP.33.5.1135","journal-title":"Hypertension"},{"key":"4552_CR56","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/10641963.2019.1601207","volume":"42","author":"Takamiya","year":"2020","unstructured":"Takamiya et al (2020) Multicenter prospective observational study of teneligliptin, a selective dipeptidyl peptidase-4 inhibitor, in patients with poorly controlled type 2 diabetes: focus on glycemic control, hypotensive effect, and safety Chikushi anti-diabetes mellitus trial. Clin Exp Hypertens 42:197\u2013204. https:\/\/doi.org\/10.1080\/10641963.2019.1601207","journal-title":"Clin Exp Hypertens"},{"key":"4552_CR57","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1161\/CIRCULATIONAHA.118.036568","volume":"139","author":"Ferdinand","year":"2019","unstructured":"Ferdinand et al (2019) Antihyperglycemic and blood pressure effects of empagliflozin in black patients with type 2 diabetes mellitus and hypertension. Circulation 139:2098\u20132109. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.036568","journal-title":"Circulation"},{"key":"4552_CR58","doi-asserted-by":"publisher","DOI":"10.1177\/2042018814560735","author":"Liakos","year":"2015","unstructured":"Liakos et al (2015) Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab. https:\/\/doi.org\/10.1177\/2042018814560735","journal-title":"Ther Adv Endocrinol Metab"},{"key":"4552_CR59","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/ac.67.2.2154211","volume":"67","author":"Goyal","year":"2012","unstructured":"Goyal, Mehta (2012) Beneficial role of spironolactone, telmisartan and their combination on isoproterenol-induced cardiac hypertrophy. Acta Cardiol 67:203\u2013211. https:\/\/doi.org\/10.1080\/ac.67.2.2154211","journal-title":"Acta Cardiol"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-022-04552-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-022-04552-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-022-04552-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T04:10:05Z","timestamp":1680235805000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-022-04552-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,13]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["4552"],"URL":"https:\/\/doi.org\/10.1007\/s11010-022-04552-8","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"type":"print","value":"0300-8177"},{"type":"electronic","value":"1573-4919"}],"subject":[],"published":{"date-parts":[[2022,9,13]]},"assertion":[{"value":"20 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No potential commercial or financial relationships are involved in the present work and the authors declare that no conflicts of interest are involved in the present research work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The experimental work was performed after approval from the Institutional Animal Ethics Committee (IAEC), Institute of Pharmacy, Nirma University, Ahmedabad (Protocol Approval No. IP\/PCOL\/PHD\/26\/2019\/007), as per the regulations of Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Government of India.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publish"}}]}}